 Since coronavirus disease 2019, COVID-19 became a global pandemic, concerns have arisen regarding the risks of COVID-19 in immunocompromised children and adolescents. Here we aim to evaluate the clinical outcomes and risks of severe COVID-19 in immunocompromised pediatric patients. Previous studies reported that most children and adolescents receiving immunosuppressive medications have clinical presentations and favorable outcomes similar to those of the general pediatric population. Treatments and access to health services should not be interrupted in these populations and continuous monitoring of the potential impact of variant strains on the risk of immunocompromised pediatric patients is warranted. This article was authored by Byung Ok-Kwak and Byung Wookoon.